Cargando…
Discovery of Polyphenolic Natural Products as SARS-CoV-2 M(pro) Inhibitors for COVID-19
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has forced the development of direct-acting antiviral drugs due to the coronavirus disease 2019 (COVID-19) pandemic. The main protease of SARS-CoV-2 is a crucial enzyme that breaks down polyproteins synthesized from the viral RNA, maki...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959258/ https://www.ncbi.nlm.nih.gov/pubmed/37259339 http://dx.doi.org/10.3390/ph16020190 |
_version_ | 1784895230706712576 |
---|---|
author | Krüger, Nadine Kronenberger, Thales Xie, Hang Rocha, Cheila Pöhlmann, Stefan Su, Haixia Xu, Yechun Laufer, Stefan A. Pillaiyar, Thanigaimalai |
author_facet | Krüger, Nadine Kronenberger, Thales Xie, Hang Rocha, Cheila Pöhlmann, Stefan Su, Haixia Xu, Yechun Laufer, Stefan A. Pillaiyar, Thanigaimalai |
author_sort | Krüger, Nadine |
collection | PubMed |
description | The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has forced the development of direct-acting antiviral drugs due to the coronavirus disease 2019 (COVID-19) pandemic. The main protease of SARS-CoV-2 is a crucial enzyme that breaks down polyproteins synthesized from the viral RNA, making it a validated target for the development of SARS-CoV-2 therapeutics. New chemical phenotypes are frequently discovered in natural goods. In the current study, we used a fluorogenic assay to test a variety of natural products for their ability to inhibit SARS-CoV-2 M(pro). Several compounds were discovered to inhibit M(pro) at low micromolar concentrations. It was possible to crystallize robinetin together with SARS-CoV-2 M(pro), and the X-ray structure revealed covalent interaction with the protease’s catalytic Cys145 site. Selected potent molecules also exhibited antiviral properties without cytotoxicity. Some of these powerful inhibitors might be utilized as lead compounds for future COVID-19 research. |
format | Online Article Text |
id | pubmed-9959258 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99592582023-02-26 Discovery of Polyphenolic Natural Products as SARS-CoV-2 M(pro) Inhibitors for COVID-19 Krüger, Nadine Kronenberger, Thales Xie, Hang Rocha, Cheila Pöhlmann, Stefan Su, Haixia Xu, Yechun Laufer, Stefan A. Pillaiyar, Thanigaimalai Pharmaceuticals (Basel) Article The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has forced the development of direct-acting antiviral drugs due to the coronavirus disease 2019 (COVID-19) pandemic. The main protease of SARS-CoV-2 is a crucial enzyme that breaks down polyproteins synthesized from the viral RNA, making it a validated target for the development of SARS-CoV-2 therapeutics. New chemical phenotypes are frequently discovered in natural goods. In the current study, we used a fluorogenic assay to test a variety of natural products for their ability to inhibit SARS-CoV-2 M(pro). Several compounds were discovered to inhibit M(pro) at low micromolar concentrations. It was possible to crystallize robinetin together with SARS-CoV-2 M(pro), and the X-ray structure revealed covalent interaction with the protease’s catalytic Cys145 site. Selected potent molecules also exhibited antiviral properties without cytotoxicity. Some of these powerful inhibitors might be utilized as lead compounds for future COVID-19 research. MDPI 2023-01-28 /pmc/articles/PMC9959258/ /pubmed/37259339 http://dx.doi.org/10.3390/ph16020190 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Krüger, Nadine Kronenberger, Thales Xie, Hang Rocha, Cheila Pöhlmann, Stefan Su, Haixia Xu, Yechun Laufer, Stefan A. Pillaiyar, Thanigaimalai Discovery of Polyphenolic Natural Products as SARS-CoV-2 M(pro) Inhibitors for COVID-19 |
title | Discovery of Polyphenolic Natural Products as SARS-CoV-2 M(pro) Inhibitors for COVID-19 |
title_full | Discovery of Polyphenolic Natural Products as SARS-CoV-2 M(pro) Inhibitors for COVID-19 |
title_fullStr | Discovery of Polyphenolic Natural Products as SARS-CoV-2 M(pro) Inhibitors for COVID-19 |
title_full_unstemmed | Discovery of Polyphenolic Natural Products as SARS-CoV-2 M(pro) Inhibitors for COVID-19 |
title_short | Discovery of Polyphenolic Natural Products as SARS-CoV-2 M(pro) Inhibitors for COVID-19 |
title_sort | discovery of polyphenolic natural products as sars-cov-2 m(pro) inhibitors for covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959258/ https://www.ncbi.nlm.nih.gov/pubmed/37259339 http://dx.doi.org/10.3390/ph16020190 |
work_keys_str_mv | AT krugernadine discoveryofpolyphenolicnaturalproductsassarscov2mproinhibitorsforcovid19 AT kronenbergerthales discoveryofpolyphenolicnaturalproductsassarscov2mproinhibitorsforcovid19 AT xiehang discoveryofpolyphenolicnaturalproductsassarscov2mproinhibitorsforcovid19 AT rochacheila discoveryofpolyphenolicnaturalproductsassarscov2mproinhibitorsforcovid19 AT pohlmannstefan discoveryofpolyphenolicnaturalproductsassarscov2mproinhibitorsforcovid19 AT suhaixia discoveryofpolyphenolicnaturalproductsassarscov2mproinhibitorsforcovid19 AT xuyechun discoveryofpolyphenolicnaturalproductsassarscov2mproinhibitorsforcovid19 AT lauferstefana discoveryofpolyphenolicnaturalproductsassarscov2mproinhibitorsforcovid19 AT pillaiyarthanigaimalai discoveryofpolyphenolicnaturalproductsassarscov2mproinhibitorsforcovid19 |